Covid-19: Les bibliothèques sont ouvertes, mais fonctionnent de manière restreinte dans le respect des mesures sanitaires en vigueur.
Veuillez consulter le site internet de votre bibliothèque pour en savoir plus.
Titre:
Sur la lèvre du volcan : roman / Patrick Moret
Auteur:Moret, Patrick, 1958- Editeur:
Lyon : Les Ed. Baudelaire
Date:
2008
Collation:
101 p. ; 21 cm
Classification:vs-bvs-sys 09.01.01 Identifiant:
9782355080623 (ISBN); http://catalogue.bnf.fr/ark:/12148/cb41271210h (URN) No RERO:
R004848390
Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts
Jung, Seungyoun, Allen, Naomi, Arslan, Alan A, Baglietto, Laura, Barricarte, Aurelio, Brinton, Louise A, Egleston, Brian L, Falk, Roni T, Fortner, Renée T, Helzlsouer, Kathy J, Gao, Yutang, Idahl, Annika, Kaaks, Rudolph, Krogh, Vittorio, Merritt, Melissa A, Lundin, Eva, Onland-Moret, N Charlotte, Rinaldi, Sabina, Schock
International journal of cancer, 15 January 2018, Vol.142(2), pp.262-270
[Revue évaluée par les pairs]
Anti-Mullerian hormone and endometrial cancer: a multi-cohort study
Fortner, Renée T, Schock, Helena, Jung, Seungyoun, Allen, Naomi E, Arslan, Alan A, Brinton, Louise A, Egleston, Brian L, Falk, Roni T, Gunter, Marc J, Helzlsouer, Kathy J, Idahl, Annika, Johnson, Theron S, Kaaks, Rudolf, Krogh, Vittorio, Lundin, Eva, Merritt, Melissa A, Navarro, Carmen, Onland-Moret, N Charlotte, Palli
British journal of cancer, 24 October 2017, Vol.117(9), pp.1412-1418
[Revue évaluée par les pairs]
Titre: Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARγ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth Auteur:Pich, Christine; Meylan, Patrick; Mastelic-Gavillet, Beatris; Nguyen, Thanh Nhan; Loyon, Romain; Trang, Bao Khanh; Moser, Hélène; Moret, Catherine; Goepfert, Christine; Hafner, Jürg; Levesque, Mitchell P; Romero, Pedro; Jandus, Camilla; Michalik, Liliane Sujet:Melanoma -- Metabolism ; Ppar Gamma -- Agonists ; Rosiglitazone -- Pharmacology ; Skin Neoplasms -- Metabolism ; Stromal Cells -- Metabolism Description:
In addition to improving insulin sensitivity in type 2 diabetes, the thiazolidinedione family of compounds and the pharmacologic activation of their best-characterized target PPARγ have been proposed as a therapeutic option for cancer treatment. In this study, we reveal a new mode of action for the thiazolidinedione rosiglitazone that can contribute to tumorigenesis. Rosiglitazone activated a tumorigenic paracrine communication program in a subset of human melanoma cells that involves the secretion of cytokines, chemokines, and angiogenic factors. This complex blend of paracrine signals activated nonmalignant fibroblasts, endothelial cells, and macrophages in a tumor-friendly way. In agreement with these data, rosiglitazone promoted human melanoma development in xenografts, and tumors exposed to rosiglitazone exhibited enhanced angiogenesis and inflammation. Together, these findings establish an important tumorigenic action of rosiglitazone in a subset of melanoma cells. Although studies...
Fait partie de:
Cancer research, 15 November 2018, Vol.78(22), pp.6447-6461
Identifiant:
1538-7445 (E-ISSN); 30185551 Version (PMID); 10.1158/0008-5472.CAN-18-0912 (DOI)
Plusieurs versions
Polymorphisms of the TUB Gene Are Associated with Body Composition and Eating Behavior in Middle-Aged Women ( TUB , Eating Behavior)
van Vliet-Ostaptchouk, Jana V, Onland-Moret, N. Charlotte, Shiri-Sverdlov, Ronit, van Gorp, Patrick J. J, Custers, Anne, Peeters, Petra H. M, Wijmenga, Cisca, Hofker, Marten H, van der Schouw, Yvonne T
PLoS ONE, 2008, Vol.3(1), p.e1405
[Revue évaluée par les pairs]
Zuercher, Patrick, Moret, Céline, Schefold, Joerg C
Swiss medical weekly, 15 July 2019, Vol.149, pp.w20111
[Revue évaluée par les pairs]
MEDLINE/PubMed (U.S. National Library of Medicine)
Titre: Dysphagia in the intensive care unit in Switzerland (DICE) - results of a national survey on the current standard of care Auteur:Zuercher, Patrick; Moret, Céline; Schefold, Joerg C Sujet:Intensive Care Units ; Deglutition Disorders -- Diagnosis Description:
Oropharyngeal dysphagia (OD) is often observed in critically ill patients. In most affected patients OD persists throughout hospital stay and negatively impacts on clinical outcomes. Here we systematically explore routine clinical practice standards for recognition/screening, diagnosis and treatment of OD in accredited Swiss ICUs. An online, 23-item questionnaire-based survey was performed to investigate current standards of care for OD in Switzerland (DICE). All (n = 49) accredited Swiss teaching hospitals providing specialist training for adult intensive care medicine were contacted. Senior intensivists were interviewed on how they would screen for, diagnose and treat OD in the ICU. The total response rate was 75.5%, with information available on all tertiary care academic centres. 67.6% (25/37) of institutions stated that they have established standard operating procedures for OD using a mostly sequential diagnostic approach (86.5%, 32/37). In 75.7% (28/37) of institutions, OD confirmation is performed without the use of instrumental techniques such as flexible (or fibre-endoscopic) evaluation of swallowing (FEES). Presumed key risk factors for OD were admission for acute neurological illness, long-term mechanical ventilation, ICU-acquired weakness and pre-existing neurological disease. Reported presumed OD-related complications typically include aspiration-induced pneumonia, increased rates of both reintubation and tracheostomy and increased ICU readmission rates. Many Swiss ICUs have established standard operating procedures, with most using sequential clinical approaches to assess ICU patients at risk of dysphagia. OD confirmation is mostly performed using non-instrumental techniques. In general, it appears that awareness of OD and ICU educational curricula can be further optimised.
Fait partie de:
Swiss medical weekly, 15 July 2019, Vol.149, pp.w20111
Identifiant:
1424-3997 (E-ISSN); 31330036 Version (PMID); 10.4414/smw.2019.20111 (DOI)